An NCCN survey taken during the period of congressional debate over new federal healthcare legislation, reports how oncology professionals feel about the possible repeal and replacement of the ACA.
Apalutamide Significantly Improves OS Vs Enzalutamide in Metastatic CSPC
Retrospective analysis data on apalutamide vs enzalutamide in patients with prostate cancer were consistent with findings from the phase 3 TITAN trial.
Forming Connections and Making a Difference in the Brain Cancer Field
The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.
Metabolic-Bariatric Surgery Reduces Pancreatic Cancer Risk in Obese Group
Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
Talazoparib/Enzalutamide Combo Prolongs Survival in Metastatic CRPC
Detailed results from the phase 3 TALAPRO-2 trial will be submitted for presentation at a future medical meeting and shared with global health authorities.